The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study

To compare the incidence of brain metastases of advanced non-small cell lung cancer (NSCLC) treated with systemic cytotoxic chemotherapy (CC) and targeted therapy (TT), we performed a large-scale, retrospective, nationwide, cohort study. The population data were extracted from the Health Insurance R...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-12, Vol.9 (1), p.18689-8, Article 18689
Main Authors: Lee, Jung Soo, Hong, Ji Hyung, Sun, Der Sheng, Won, Hye Sung, Kim, Yeo Hyung, Ahn, Mi Sun, Kang, Seok Yun, Lee, Hyun Woo, Ko, Yoon Ho
Format: Article
Language:English
Subjects:
631/67/1612/1350
692/4028/67/1612/1350
Aged
Antineoplastic Agents - therapeutic use
Brain
Brain cancer
Brain Neoplasms - secondary
Brain Neoplasms - therapy
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Cohort analysis
Combined Modality Therapy
Female
Health risk assessment
Humanities and Social Sciences
Humans
Incidence
Lung cancer
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Metastases
Metastasis
Middle Aged
multidisciplinary
Neoplasm Metastasis
Non-small cell lung carcinoma
Palliative Care
Population studies
Population-based studies
Republic of Korea - epidemiology
Retrospective Studies
Risk Factors
Science
Science (multidisciplinary)
Toxicity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the incidence of brain metastases of advanced non-small cell lung cancer (NSCLC) treated with systemic cytotoxic chemotherapy (CC) and targeted therapy (TT), we performed a large-scale, retrospective, nationwide, cohort study. The population data were extracted from the Health Insurance Review and Assessment Service of Korea database from January 1, 2011, to November 30, 2016. Of the 29,174 patients newly diagnosed with stage IIIB or IV NSCLC who received systemic treatment, we investigated the initial and subsequent incidence of brain metastases. Besides, among 22,458 patients without initial brain metastasis, the overall cumulative incidence of subsequent brain metastases was compared according to systemic treatment administered. In total, 1,126 (5.0%) patients subsequently developed brain metastasis. The overall cumulative incidence of brain metastasis was significantly higher in the TT group than in the CC group (1-year cumulative incidence: 8.7% vs. 3.8%; 3-year: 17.2% vs. 5.0%; P 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-019-55150-6